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Abstract Mutations in the gene encoding of the catalytic
subunit of mtDNA polymerase gamma (POLG1) can cause
typicalAlpers’syndrome.Recently,anewPOLG1mutation
phenotype was described, the so-called juvenile-onset
Alpers’ syndrome. This POLG1 mutation phenotype is
characterized by refractory epilepsy with recurrent status
epilepticus and episodes of epilepsia partialis continua,
which often necessitate admission to the intensive care unit
(ICU)andposeanimportantmortalityrisk.Wedescribetwo
previously healthy unrelated teenage girls, who both were
admitted with generalized tonic-clonic seizures and visual
symptoms leading to a DNA-supported diagnosis of juve-
nile-onset Alpers’ syndrome. Despite combined treatment
with anti-epileptic drugs, both patients developed status
epilepticus requiring admission to the ICU. Intravenous
magnesium as anti-convulsant therapy was initiated, result-
ing in clinical and neurophysiological improvement and
rapid extubation of both patients. Treating status epilepticus
in juvenile-onset Alpers’ syndrome with magnesium has
not been described previously. Given the difﬁculties
encountered while treating epilepsy in patients with this
syndrome, magnesium therapy might be considered.
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Introduction
Polymerase gamma is essential for mitochondrial DNA
replication. Mutations in the nuclear gene encoding the
catalytic subunit of mtDNA polymerase gamma (POLG1)
are associated with mitochondrial diseases [1]. POLG1
mutations have been implicated in progressive external
ophthalmoplegia [2], sensory ataxic neuropathy [3], par-
kinsonism [4], premature menopause [4], Alpers’ syn-
drome [5, 6], and mixed phenotypes [7, 8]. There appears
no strict relationship between phenotype and genotype in
patients with pathogenic mutations in the gene that encodes
for POLG1 [8].
Alpers’ syndrome usually presents in early childhood
with the classical triad of developmental delay, intractable
seizures and hepatic failure, which may be precipitated by
valproic acid [3, 5–8]. In 2008, a new POLG1 mutation
phenotype was described, features of which are refractory
epilepsy and visual symptoms in previously healthy ado-
lescents or young adults, the so-called juvenile-onset
Alpers’ syndrome [9, 10]. Both Alpers’ phenotypes are
characterized by refractory epilepsy with recurrent status
epilepticus and episodes of epilepsia partialis continua,
which often necessitate admission to the intensive-care unit
(ICU) and pose an important mortality risk [10].
Intravenous magnesium is the ﬁrst choice agent in
treating convulsions in eclampsia [11], and may be effec-
tive in status epilepticus of other origin, although reports
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DOI 10.1007/s00415-010-5721-2on this topic are sparse [12–14]. We present two cases of
non-related teenage girls with juvenile-onset Alpers’ syn-
drome due to POLG1 mutations who presented with
refractory seizures that originated in the occipital lobe and
were eventually successfully treated with magnesium.
Case 1
A previously healthy 19-year-old woman was admitted to
our tertiary care center after two generalized tonic clonic
seizures in a fortnight. Since the ﬁrst seizure, she com-
plained of seeing bright spots. Routine neurological
examination and brain-CT at admission showed no
abnormalities. Visual ﬁeld examination revealed a right-
sided homonymous paracentral scotoma. FLAIR and T2-
weighted MRI showed bilateral lesions with increased
signal intensity in the occipital cortex, most prominent in
the left hemisphere, with areas of both increased and
decreased diffusion on ADC maps. EEG showed slowing
of the background activity and continuous epileptic activity
over the occipital areas, also most prominent in the left
hemisphere. Her visual symptoms were therefore inter-
preted as focal occipital status epilepticus. Treatment with
phenytoin and continuous intravenous infusion of
clonazepam were initiated. This improved the visual
complaints but they did not resolve completely.
Five weeks after the ﬁrst seizure, while still on phe-
nytoin and clonazepam she experienced right-sided focal
motor seizures that only partially responded to additional
therapy with clobazam and levetiracetam. Since a POLG1
mutation syndrome was suspected, valproic acid was
avoided. Treatment with midazolam resulted in temporary
resolution of focal convulsions, but her visual complaints
did not improve and ictal activity persisted on EEG with
right-sided hemiparesis. Her mental status deteriorated as
she became disoriented, with dysphasia and acalculia.
Repeated MRI showed an increase in the extent and
number of the cortical occipital lesions, now including left-
sided pulvinar thalamic abnormalities. Urgent DNA anal-
ysis indeed revealed a homozygous (A467T) mutation of
the POLG1-gene conﬁrming the diagnosis of juvenile-
onset Alpers’ syndrome.
Herconditionworsenedasshedevelopedfrequentsimple
left-sided partial motor seizures, which gradually trans-
formedintogeneralizedstatusepilepticus.Shewasadmitted
to the ICU and treated with high-dose intravenous midazo-
lam (0.4 mg/kg/h), and a combination of phenytoin
(300 mg/day i.v.), clonazepam (3 mg/day i.v.) and leveti-
racetam (1,500 mg/day i.v.), and ventilatory support
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123(Fig. 1). When sedation was tempered, the seizures imme-
diately returned. High-dose oral topiramate (1,000 mg/day)
somewhat decreased the frequency of the seizures but the
EEGs remained highly abnormal, showing encephalopathic
changes with continuous epileptic activity. Magnesium
infusion was then introduced, aiming to increase serum
levels from 0.81 mmol/l to approximately 3.5 mmol/l,
leading almost instantly to complete abolishment of her
clinical seizures. Midazolam was tapered, and she was ex-
tubated the following day. At time of extubation, serum
magnesium level was 3.8 mmol/l. After extubation, she was
able to communicate, although she remained somnolent.
Although clinical signs of seizures remained absent, the
patient developed sepsis, probably due to ventilator asso-
ciated pneumonia, leading to multi-organ failure and death
2 weeks after admission to the ICU.
Case 2
In December 2008, a previously healthy 17-year-old girl
complained of impaired vision and light ﬂashes for several
weeks. She was evaluated in another hospital after a
15-min episode of confusion and suspected convulsions.
She fully recovered and was diagnosed with migraine. Two
days later, she had two generalized tonic-clonic seizures,
and was admitted to our hospital. Neurological examina-
tion revealed dysphasia, right-sided hemiparesis and
intermittent partial motor seizures of her right leg. T2 and
FLAIR MRI showed hyperintense lesions of the left
occipital cortex, thalamus, and mesial temporal lobe. One
week after admission, DNA analysis revealed a homozy-
gous A467T mutation of the POLG1-gene, conﬁrming the
suspected diagnosis of juvenile-onset Alpers’ syndrome.
Fourteen years earlier, her teenage sister had generalized
status epilepticus. She died without an established diag-
nosis after a complicated brain biopsy.
While being treated with phenytoin (Fig. 1), her EEG
showed a continuing focal status epilepticus of the left
occipital region, spreading anteriorly. Continuous intrave-
nous infusion of midazolam and levetiracetam were added
and she was admitted to the ICU for ventilatory support.
When high-dose midazolam (0.3 mg/kg/h), levetiracetam
(2,000 mg/day i.v.), and phenytoin (300 mg/day i.v.) could
not abolish focal status epilepticus, magnesium infusion
was started, aiming to increase serum levels from
0.85 mmol/l to approximately 3.5 mmol/l. Paresis and
dysphasia both gradually improved within hours after the
start of magnesium infusion and within 12 h midazolam
was tapered and she was extubated with at that time a
serum magnesium level of 2.0 mmol/l. EEG after extuba-
tion showed improvement, although there was still a focal
occipital status epilepticus (Fig. 2).
When magnesium was tapered and midazolam was
discontinued, focal convulsions of her right arm recurred,
for which midazolam (0.1 mg/kg/h) was restarted in
addition to magnesium, phenytoin, and clobazam. Con-
vulsions ceased and the right-sided (post-)ictal paresis and
dysphasia disappeared. Gradually, midazolam and magne-
sium were stopped and oral phenytoin, clobazam, and
levetiracetam were continued. The patient could be dis-
charged 1 month after admission, and she remains without
seizures up to now, 8 months after discharge. Her EEG at
discharge showed subtle focal occipital epileptic dis-
charges, although there was an obvious improvement
compared to previous EEGs.
Discussion
Juvenile-onset Alpers’ syndrome is characterized by
refractory epilepsy, predominating in the occipital lobe,
with frequent episodes of spreading and status epilepticus,
for which a combination of several anti-epileptic drugs
(AEDs) is often required [10]. Benzodiazepines are the
main-stay in the treatment of status epilepticus, but often
necessitate ventilatory support. Importantly, valproic acid
should be avoided, since it carries a high risk of inducing
hepatic failure. In our own experience, propofol and thio-
pental may also lead to hepatic failure and rapid neuro-
logical deterioration in children with Alpers’ syndrome. In
juvenile-onset patients with POLG1 mutations, these drugs
should perhaps also be avoided. When the combination of
several high-dose AEDs could not stop focal or generalized
status epilepticus in our two patients, we chose to add
magnesium according to the use in (pre-)eclampsia [11].
The anticonvulsive effect of magnesium has been well
established in (pre-)eclampsia, but it is rarely used in the
treatment of epilepsy of other origin. In (pre-)eclampsia, an
immediate effect is pursued by a loading dose of magne-
sium sulphate followed by continuous infusion for 24 h,
resulting in serum magnesium levels of 1.7–3.5 mmol/l
[15], but even at these high doses, side-effects are mild and
sparse [11, 16]. In particular, renal or hepatic failure due to
high-dose magnesium therapy have not been described.
Although magnesium is effective in preventing and treating
eclampsia, its mechanism of action remains unclear. One of
the suggested anticonvulsant mechanisms is its action as a
N-methyl-D-aspartic acid (NMDA-) receptor antagonist.
The NMDA-receptor is a glutamate receptor which, when
activated, leads to a massive depolarization of neuronal
networks and bursts of action potentials. Magnesium may
act to increase the seizure threshold by blocking the
NMDA-receptors [15]. Animal models suggest that
AEDs enhancing GABA-receptor activation (e.g., barbi-
turates and benzodiazepines) are effective in the
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123treatment of status epilepticus but resistance often
develops over prolonged status epilepticus. Ketamine,
which is also an NMDA-receptor antagonist, however,
showed no effect when administered within the hour
after onset of status epilepticus, but was effective in
treating prolonged status epilepticus, suggesting a shift
from inadequate GABA-ergic inhibition to excessive
glutamergic excitation in refractory status epilepticus [17,
18]. Magnesium also acts as a voltage-dependent calcium
channel antagonist and prevents membrane depolariza-
tions, which could be an additional mechanism of anti-
epileptic action [19].
Fig. 2 a (case 2): EEG before
magnesium infusion. Despite
midazolam, levetiracetam, and
phenytoin, there is an ongoing
status epilepticus of the left
hemisphere. b (case 2): EEG
about 10 h after the start of
magnesium infusion. There is a
marked loss of rhythmicity and
improved background over the
left and right hemisphere. Left
and right arrow 1s ;up and
down arrow 200 lV
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123The potential use of magnesium in epilepsy is adapted
from practice in eclampsia [11]. While magnesium as an
anticonvulsant agent has been tested to be safe in (preg-
nant) women, the safety of using magnesium for treating
epilepsy in adolescents with juvenile-onset Alpers’ syn-
drome has not been studied. We cannot of course be certain
that the magnesium infusion was the key factor in termi-
nating otherwise refractory status in our two patients,
particularly in the second case who resolved some hours
later. However, the timing in the ﬁrst, together with bio-
logical plausibility, is persuasive. Given the difﬁculties
encountered while treating refractory status epilepticus in
patients with juvenile-onset Alpers’ syndrome, and the
potential danger of some commonly used antiepileptic
drugs in this syndrome, additional magnesium therapy
should be considered.
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